ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: A phase II study (NCT03516279) is assessing pembrolizumab and ABL1 kinase inhibitor (dasatinib, imatinib, or nilotinib) for patients with CML and persistently detectable minimal residual disease.